Phase I/II evaluation of RV1001, a novel PI3Kδ inhibitor, in spontaneous canine lymphoma.
Gardner HL, Rippy SB, Bear MD, Cronin KL, Heeb H, Burr H, Cannon CM, Penmetsa KV, Viswanadha S, Vakkalanka S, London CA.
Gardner HL, et al. Among authors: heeb h.
PLoS One. 2018 Apr 24;13(4):e0195357. doi: 10.1371/journal.pone.0195357. eCollection 2018.
PLoS One. 2018.
PMID: 29689086
Free PMC article.
Clinical Trial.